TriSalus Life Sciences, Inc. Business Combination, Acquisition Related Costs
TriSalus Life Sciences, Inc. (TLSI) reported Business Combination, Acquisition Related Costs of $40.00 million for the 1-month period ending 2023-05-13, per its 10-Q filed 2023-08-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2023-08-02
- TriSalus Life Sciences, Inc. business combination, acquisition related costs for the quarter ending 2023-03-31 was $40.00M.
- TriSalus Life Sciences, Inc. business combination, acquisition related costs for fiscal 2022 was $40.00M.
| Period end | Business Combination, Acquisition Related Costs 1 month | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|
| 2023-05-13 | $40.00M 10-Q · filed 2023-08-02 | ||
| 2023-03-31 | $40.00M 10-Q · filed 2023-05-12 | ||
| 2022-12-31 | $40.00M 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |